Bladder Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with bladder cancer (a type called urothelial carcinoma) confirmed by a tissue or cell sample. If the cancer is a mixed type, the main type must be the traditional urothelial (transitional cell) pattern.
• People whose bladder cancer has been staged as T2 through T4a, with no confirmed distant spread, and whose medical team considers chemoradiation (combined chemotherapy and radiation therapy) an appropriate treatment approach.
• People who are planned to have a TURBT procedure (a surgery to remove bladder tumour tissue through the urethra) before starting chemoradiation, as part of their normal treatment plan.
• People whose kidneys are functioning well enough, based on blood test results showing creatinine below 2 mg/dL or a calculated kidney function score above 30 ml/min.
• People who are able to understand the study and are willing to sign a consent form agreeing to take part.
• People of childbearing potential, and men whose partners could become pregnant, who agree to use reliable contraception before, during, and for 90 days after the study treatment ends. If pregnancy occurs or is suspected during the study, the treating doctor must be informed immediately.

Who may not be able to join:

• People whose urothelial cancer originates only in the ureter, urethra, or kidney (renal pelvis) and does not involve the bladder.
• People who have known cancer that has spread to distant parts of the body, such as the lungs or liver. (Note: People with cancer-affected lymph nodes in the abdomen or pelvis may still be considered if surgery to remove all the cancer is planned — confirm with trial site.)
• People who have bladder abnormalities that would make it unsafe to place small internal markers (called fiducial markers) in the bladder, such as large pouches in the bladder wall or active or recurring urinary infections.
• People who have previously had, or are planned to have, full-dose radiation directed at the bladder as a definitive treatment.
• People who have received chemotherapy or biological therapy directly into the bladder within 6 weeks before the first treatment in the study.
• People who are planned to receive immunotherapy drugs as a neoadjuvant (pre-treatment) systemic therapy. (Note: Prior BCG treatment, a common bladder cancer therapy, does not disqualify someone.)
• People who have a significant active infection or a serious uncontrolled medical condition that would make study participation unsafe.
• People who are currently pregnant or breastfeeding.
• People with a history of another cancer (other than urothelial carcinoma) that, in the treating doctor's judgement, is likely to interfere with the study treatment.
• People with severe kidney failure who cannot safely receive the contrast dye used in MRI scans.

Important: Always verify eligibility with the trial site directly before applying.